Welcome to the Inaugural Next Generation Cancer Vaccine Development Summit

Cancer remains one of the most challenging diseases we face today. With standard treatment protocols consisting of chemotherapy, radiotherapy, and surgical intervention often being hampered by toxic side effects and concomitant malignancies, vaccines offer a promising alternative to unleash the most powerful force against cancer: our own immune system.

With a better understanding of which antigens to target, advances in combination therapies, and recent approvals of newer vaccine platforms, the re-emergence of cancer vaccines has been met with promising clinical data, renewed investments, and unprecedented industry partnerships.

The first Next Generation Cancer Vaccine Development Summit will focus on overcoming the translational and clinical challenges of developing cancer vaccines, including finding the right antigens, reassessing patient populations, understanding immune suppression and resistance patterns, and exploring case studies covering Ovarian Cancer, Pancreatic Cancer, Glioblastoma, Lung Cancer, Melanoma, Malignant pleural mesothelioma (MPM), Prostate Cancer, and Advanced Solid Tumors.

With a focus on mRNA, DNA, peptide, and other next-gen vaccines, this niche 3-day agenda has been specifically designed to help industry experts to:

Cancer Vaccines Bullet

Progress your own expertise and experience while forging complementary partnerships and alliances

Cancer Vaccines Bullet

Overcome immunogenicity challenges and design safe and efficacious vaccine formulations

Cancer Vaccines Bullet

Define clinically meaningful endpoints to successfully develop and safely deliver optimal doses for patient use

The digital Next Generation Cancer Vaccine Development Summit is not only the first, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing mRNA, DNA, peptide, and other next gen platforms to bring new cancer immunotherapies to market.

Expert Speaker Faculty Includes:

Niranjan Sardesai

Chief Executive Officer

Geneos Therapeutics

Karin Jooss

Chief Scientific Officer

Gritstone Oncology

Alejandro Sepulveda

Scientific Director, Head of Cancer Vaccines


Lena Kranz

Director Cancer Vaccines


Tom Davis

Chief Medical Officer

Genocea Biosciences

Victor Levitsky

Chief Scientific Officer


Laurent Humeau

Chief Scientific Officer


Mark Findeis

Executive Director, Research Biochemistry

Agenus Bio

Lead Partner